Basic Information

Gene symbol CSF2 Synonyms CSF, GMCSF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description colony stimulating factor 2


GTO ID GTC4000
Trial ID NCT01598129
Disease Solid Tumor
Altered gene E1A|CSF2
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment ONCOS-102|CGTG-102
Co-treatment cyclophosphamide
PhasePhase1
Recruitment statusCompleted
TitleExploratory Open Label Study of GM-CSF Coding Oncolytic Adenovirus CGTG-102, With Low Dose Cyclophosphamide in Patients With Refractory Injectable Solid Tumours
Year2012
CountryFinland
Company sponsorTargovax Oy
Other ID(s)Oncos-C1
Vector information
Vectoradenovirus
ConstructAd5/3-delta24-GMCSF
Vector typeserotype 5 adenovirus
Transgene/Inserted geneGM-CSF, which enhances antitumor immunity by recruiting antigen-presenting cells (APCs) and natural killer (NK) cells, activates and matures APCs at the tumor site, thereby potentiating the ability of ONCOS-102 to induce cellular immunity against the tumor in which it replicates.
Viral genome modificationONCOS-102 has a genetically modified fiber with a serotype 3 knob for enhanced gene delivery to cancer cells. A 24-bp deletion has been made in the Rb binding site of the E1A gene.
Additional featureGM-CSF

Clinical Result

Cohort 1
Administration route intratumoral injection|intravenous infusion|oral
Dosage CGTG-102, on day 1, 4, 8, 15, 29, 57, 85, 113 and 141|cyclophosphamide, 1 pill per day, start on the day after the first injection and last until visit day 169
Pts 12
Age Adult, Older_Adult
Adverse reactions 5/12(Gastrointestinal disorders; Hepatobiliary disorders; Musculoskeletal and connective tissue disorders)
References PMID: 26981247

Relationship Graph

Overview of Knowledge Graph